Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 767

Sort by

Sort Order Select

Journal Articles

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

Blood blood.2024027902.

https://doi.org/10.1182/blood.2024027902

Published: 2025

Includes: Supplemental data

Journal Articles

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Blood blood.2025028833.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Blood blood.2024027287.

https://doi.org/10.1182/blood.2024027287

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results

Blood blood.2024027620.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes

Blood blood.2024026236.

https://doi.org/10.1182/blood.2024026236

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Blood blood.2024027336.

https://doi.org/10.1182/blood.2024027336

Published: 2025

Includes: Supplemental data

Journal Articles

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

Blood blood.2024025643.

https://doi.org/10.1182/blood.2024025643

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Dr, Martine Escoffre-Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean Marc Schiano de Colella, Mourad Tiab, Mohamad Mohty, Frédérique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hébraud, Laurent Flet, Jean-Valère Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cécile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Hélène Demarquette, Valentine Richez, Cherel Bruiec, Laurent Frenzel, Marie-Christiane MB Vekemans, Noemie Bigot, Hervé Avet-Loiseau, Jill Corre, Philippe Moreau

Blood blood.2024026230.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Inga M. Schimansky, Andreas Tiede, Christiane Dobbelstein, Dr. Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul N. Knöbl, Johannes Oldenburg, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Moehnle, Katharina Holstein, Wolfgang A. Miesbach

Blood (2024) 144 (Supplement 1): 555.

https://doi.org/10.1182/blood-2024-205490

Published: 2024

Journal Articles

Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

Frank W.G. Leebeek, Karina Meijer, Michiel Coppens, Peter Kampmann, Dr. Klamroth, Paul van der Valk, Paul E. Monahan, Karen Pinachyan, Sandra LeQuellec, Wolfgang Miesbach

Blood (2024) 144 (Supplement 1): 3578.

https://doi.org/10.1182/blood-2024-198379

Published: 2024

Journal Articles

Immunotherapy with pVAX14 Nucleic Acid in Combination with All-Trans Retinoic Acid (ATRA) in an Acute Promyelocytic Leukemia (APL) Mouse Model Activates Cytotoxic T-Cells and Enhances Immune Responses: A Strategy for Turning “Cold” Tumors “Hot”

Rose Ann Padua, Satyananda Patel, James Smith, Dr Omidvar, Nilgun Tekin, Fabien Guidez, Mathieu Chiquet, Niclas Setterblad, Ken I Mills, Marika PLA, Patricia Krief, Thierry Huet, Christine Chomienne, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2024-201513

Published: 2024

Journal Articles

Impact of Variable Recombinant Factor VIII Binding on Platelet Functions

Anja Strebel, Fabrizio Pennacchio, Sebastian Lickert, Dr. Klamroth, Viola Vogel

Blood (2024) 144 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2024-193865

Published: 2024

Journal Articles

Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Beta Thalassemia Major: Experience from Resource Constrained Centers

Khalil Ur Rahman, Parvez Ahmed, Shahzad Sarwar, Shahzad Nasir, Umar Zahur, Muhammad Nadeem, Saba Tazeen, Summaira Naseeb, Uzair Ahmed, Dr Asghar Ali, Hina Peter, Muhammad Afzal, Qamar Un Nisa Chaudhry, Syed Karman Mahmood, Sumyyia Abbasi, Mehroz Fatima

Blood (2024) 144 (Supplement 1): 7296.

https://doi.org/10.1182/blood-2024-210225

Published: 2024

Journal Articles

To Study Outcomes in Young CML Treated with TKI. a Registry Data from Hematological Cancer Consortium (HCC) of India

Blood (2023) 142 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2023-181369

Published: 2023

Journal Articles

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Dr. Peters, Peter Bader, Ulrike Pötschger, M. Akif Yesilipek, Herbert Pichler, Franco Locatelli, Raquel Staciuk, Adriana Balduzzi, Gergely Krivan, Marianne Ifversen, Cristina Díaz De Heredia, Marc Bierings, Jacek Wachowiak, Jean-Hugues Dalle

Blood (2023) 142 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2023-185870

Published: 2023

Journal Articles

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Prof. Uttam Kumar Nath, Karthik Kumar, Adamya Gupta, Reshma Benson, DR Arjun Kachhwaha

Blood (2023) 142 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2023-188377

Published: 2023

Journal Articles

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 473.

https://doi.org/10.1182/blood-2023-172704

Published: 2023

Journal Articles

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Krzysztof Kalwak, Peter Bader, Jean-Hugues Dalle, Petr Sedlacek, Jochen Buechner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Diaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Ulrike Poetschger, Dr. Peters, Franco Locatelli

Blood (2023) 142 (Supplement 1): 232.

https://doi.org/10.1182/blood-2023-180728

Published: 2023

Journal Articles

Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Eight Year Data from MIOT International, Chennai, India

Kishore Kumar, Chezhian Subash, Durai Prabhu, Manikandan R, Senthooran Dr

Blood (2023) 142 (Supplement 1): 6178.

https://doi.org/10.1182/blood-2023-172649

Published: 2023

Journal Articles

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Susan Klaeger, Eugen Tausch, Binyamin A. Knisbacher, Annie Apffel, Karl R Clauser, Corinne Williams, Clary Clish, Laura Z. Rassenti, Thomas J. Kipps, Kirsten Fischer, Michael Hallek, Michael A Gillette, Donna S. Neuberg, Gad Getz, DR Mani, Stephan Stilgenbauer, Catherine J. Wu, Steven A Carr

Blood (2022) 140 (Supplement 1): 9838–9839.

https://doi.org/10.1182/blood-2022-167843

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy

Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis

Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results

Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

Immunotherapy with pVAX14 Nucleic Acid in Combination with All-Trans Retinoic Acid (ATRA) in an Acute Promyelocytic Leukemia (APL) Mouse Model Activates Cytotoxic T-Cells and Enhances Immune Responses: A Strategy for Turning “Cold” Tumors “Hot”

Impact of Variable Recombinant Factor VIII Binding on Platelet Functions

Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Beta Thalassemia Major: Experience from Resource Constrained Centers

To Study Outcomes in Young CML Treated with TKI. a Registry Data from Hematological Cancer Consortium (HCC) of India

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Eight Year Data from MIOT International, Chennai, India

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only